Neuropsychiatry
To help patients with psychiatric and neurological disorders to restore their social integration we offer a variety of products in this area.
Product Media
Aripiracare®
Aripiracare®
showed a significant effect on both positive and negative symptoms of schizophrenia and schizoaffective disorder.
More details
showed a significant effect on both positive and negative symptoms of schizophrenia and schizoaffective disorder.
Aripiprazole 10mg
Aripiprazole 20mg
Aripipracare is indicated for the treatment of schizophrenia in adults and adolescents
Aripipracare is indicated for the treatment of moderate to severe manic orders in Bipolar I predominantly disorder and for the prevention of new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.
The Recommended starting dose for Aripipracare is 10 or 20mg/day without regard to meal, maximum daily dose should not exceed 30mg/day
Due to α1-adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive medicinal products.
Given the primary CNS effects of aripiprazole, caution should be used when aripiprazole is administrated in combination with alcohol or other CNS medicinal products with overlapping adverse actions such as sedation.
If aripiprazole is administrated concomitantly with medicinal products known to cause QT prolongation or electrolyte imbalance, caution should be used
A carton box containing 1, 2, 3 (AL/Opaque white PVC) strips of 10 tablets and an inner leaflet.
Store at temperature not exceeding 30 °C, in a dry place, Keep out of reach of children.
Related Products
